Different 5-FC prodrug application regimes result in different oncolytic efficiencies

Measles vaccine virus (MeV) already has been demonstrated to be safe when lysing tumor cells (Galanis et al., 2010). However, when monitoring the expression of the MeV encoded reporter gene CEA it was found (i) that only few tumor cells were infected by MeV and (ii) that subsequent to initial tumor colonization no substantial production of progeny MeV particles took place in the respective cancer patients (Russell, Peng & Bell, 2012). These early clinical results point out the necessity for an enhancement of oncolytic effectiveness of MeV-based virotherapeutics. We are developing a recombinant armed measles vacc…